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The myocardium takes up twomajor substrates: glucose and fatty acids, and various methods have been used to
evaluate this uptake. Despite extensive study of radiotracer uptake-basedmethods, however, an easily applicable
datasheet has not previously been provided. In this manuscript, an example of a method involving an easily
modiﬁed data sheet based on dual tracer methods is presented.
This method, with its data sheet:
 Is applicable to all radiotracers, regardless of decay time
 Is useful, simple, and modiﬁable; and
 Is applicable to small animal studies.
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In this methodological study, myocardial glucose and fatty acid uptake were measured using
18F-ﬂuorodeoxyglucose (18FDG) and 125I-labeled fatty acid tracer, respectively [1,2]. The fatty acid
tracers comprise 125I-iodophenyl 9-methylpentadecanoic acid (125I-9MPA) which is incorporated and
rapidly metabolized to iodophenyl-3-methylnonanoic acid by beta-oxidation and retained in the
myocardium [3] and 125I-BMIPP, 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid, which is
another fatty acid tracer and metabolized by b oxidation and retained in the myocardium [4]. The
radioactive half-lives of 18FDG and 125I-labeled fatty acid tracer are 110min and 60days, respectively.
The dual tracermethods utilize the difference in decay times, the energy peaks, and the doses injected
of two tracers. For example, rats were fasted overnight, simultaneously injectedwith about 0.5–1mCi
of 18FDG and about 10–20mCi of 125I-lrabeled fatty acid tracer, and euthanized by decapitation 45min
[(Fig._1)TD$FIG]
Fig. 1. (A) Autoradiography of 18F-ﬂuorodeoxyglucose (18FDG) at the ﬁrst analysis. (B) Autoradiography of 125I-iodophenyl 9-
methylpentadecanoic acid (125I-9MPA) at the second analysis.
When 18FDG images were acquired (A), graded standards of both 18FDG which consisted 18FDG only and 125I-9MPA which
consisted 125I-9MPA olny as described in [50_TD$DIFF]second method in the section 2 in Measurement of radioisotope activity were placed
on the sheet.When 125I-9MPA imageswere acquired 9days after the ﬁrst experiment (B), the same sheetwas exposed; note that
the 18FDG standards had completely decayed. The respective 18FDG and 125I-9MPA doses per rat were 436mCi (16.1 MBq) and
11.6mCi (0.43 MBq). The arrow indicates graded 18FDG standards. Arrowheads indicate graded 125I-9MPA standards.
Table 1
Advantages and disadvantages of radioactive and stable tracers.
Advantages Disadvantages
Radioactive In vivo imaging available by PET or SPECT; relatively easy
clinical application Autoradiography
Some tracers have a very short decay time
systems and activity counters widely available for ex vivo
analysis
Some tracers are trapped, and only
substrate uptake is analyzed
Dual-tracer methods utilize different decay times, energy
peaks, and dosages






Fluxome analysis of intermediate metabolites from tracers
using nuclear magnetic resonance (NMR) or gas
chromatography mass spectrometry (GC–MS)
Difﬁculties with in vivo analysis
Complex metabolic networks can be analyzed Expensive tracers and equipment
Do not decay or emit radiation Natural abundance of a given isotope (and
presence of multiple other isotopes) must
be low
Amounts should be sufﬁciently large to
account for when calculating a metabolic
rate
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after injection. Hearts were removed from the rats and washed in cold saline. A portion comprising
one third of the apical side was frozen in liquid nitrogen, and radioisotopic activity was measured
using a scintillation counter. Mid-ventricle specimens were embedded in methylcellulose, cut into
serial 20-mm-thick transverse sections, and analyzed using a computer-assisted imaging-processing
system. The analyzed portion of the heart is provided as an analytical example. To measure
125I-labeled fatty acid tracer uptake, radioisotopic activity was measured at least 48h after the initial
measurements. The amount of incorporated radioisotope was reported as a percentage of the
administered dose, corrected by heart weight in grams, or as a standard uptake value (SUV) of the
tissue concentration (mCi/g)/injected dose (mCi)/body weight (g). Cross-talk between the two tracers
was negligible (Fig. 1A and B).
Radioisotope preparation
1. Determine the total radioisotopic activity of 18FDG and 125I-labeled fatty acid tracer
2. Mix 18FDG and 125I-labeled fatty acid tracer with saline to a ﬁnal injection volume
(100–200mlnumber of rats to inject plus 5) containing 500mCi–1 mCi of 18FDG and
10–20mCi of 125I-labeled fatty acid tracer. Note that the prepared volume should be greater than
the precise volume [100–200ml (number of rats plus 5)]. If mice are used, an injection volume of
20–50ml per mouse is appropriate [5,6].
3. Fill in the date, measured dose, measured time, and numbers used for preparation, as well as the
time at the start of the experiment in the data sheet (supplemental materials). This will allow
automatic calculation of the radioisotope activity at the start of the experiment.
Animal methods
Animal care and experimental procedures were approved by the Institutional Animal Care and Use
Committee of Kyoto University and conducted following the Guide for Care and Use of Laboratory
Animals published by the United States National Institutes of Health.
1. Assess the body weight and cardiac function in advance. Monitor blood glucose using a self-
monitoring blood glucose kit to determine whether 18FDG uptake is inﬂuenced by blood glucose
levels.
2. In rats fasted overnight, insert a plastic needle (24-gauge) attached to a thin tube containing saline
into the tail vein. Inject a 100–200-ml volume containing 1 mCi of 18FDG and 20mCi of 125I-labeled
fatty acid tracer simultaneously, followed by saline to wash the tube.
3. Euthanize animals via decapitation or deep sedation 45min after injection; remove the hearts and
place them in cold saline.
4. Collect blood, wash hearts quickly in saline, and weigh each heart
5. Embedmid-ventricle specimens inmethylcellulose, and freeze them on dry ice. Collect andweigh a
one-third portion of the apical side and freeze this tissue in liquid nitrogen. This will be used to
measure radioisotopic activity with a scintillation counter. The analyzed portion of the heart is
provided as an analytical example.
Measurement of radioisotope activity using a scintillation counter
1 Count the levels of 18FDG or 125I-labeled fatty acid tracer in the above-described apical portion via
direct measurement with a scintillation counter. Window levels should be set in advance at 15–
75KeV for 125I and 250–750KeV for 18F. The energy peak of 18FDG is 511KeV; that of 125I-9MPA is
35KeV. The counting efﬁciency speciﬁc to the scintillation counter should also be known before the
experiment. For this manuscript, a 12-s counting periodwas appropriate for the proscribed settings
and doses. The ﬁrst count is acquired to determine the 18F uptake in the one-third apical portion of
the heart. This data should be ﬁlled in the yellow-colored cells of the second Excel sheet. In the ﬁrst
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experiment, the 18FDG activitywas not inﬂuenced by the 125I-labeled fatty acid tracer activity due to
the narrow energy peak and difference in the injected dose; however, the 125I-labeled fatty acid
tracer activity measured during the ﬁrst analysis exceeded the actual values; 18FDG has a relatively
scattered energy peak and these values are not usually used in the analyses. Fill in the values in the
second Excel sheet attached as a supplemental Excel ﬁle.
2 Two methods exist for the preparation of graded standards
-[51_TD$DIFF] The ﬁrst involves a count of the mixed radioisotopes for injection. Prepare duplicates of the
following:5–10ml of themixedradioisotopes(A),5–10ml ofa2volumeof themixedradioisotopes
diluted in saline (B), 5–10ml of a 4 volumeof themixed radioisotopes diluted in saline (C), 5–10ml
of an [13_TD$DIFF]8 volumeof themixed radioisotopes diluted in saline (D), and 5–10ml of a 16 volumeof the
mixed radioisotopes diluted in saline (E). These will be used to calculate standard curves of known
injected doses and actual counts. Count, seal, and preserve these standard samples. Note: do not
discard these standard tubesbecause theywill beneeded for the second count and 125I-labeled fatty
acid tracer calculation. Fill in the time of graded standard measurement, the volumes of graded
standards (usually the same volume), and radioisotope activity in the ﬁrst Excel datasheet
(Supplemental materials)
- The second method is the count of each of the used radioisotopes respectively, for which two
separate graded standards will be prepared. Prepare duplicates of the following: 5–10ml of the
prepared 18FDG (pre-mixed) (A), 5–10ml of a 2 volume of the prepared 18FDG (pre-mixed)
diluted in saline (B), 5–10ml of a 4 volume of the prepared 18FDG (pre-mixed) diluted in saline
(C), 5–10ml of an [13_TD$DIFF]8 volume of the prepared 18FDG (pre-mixed) diluted in saline (D), and 5–10ml
of a 16 volume of the prepared 18FDG (pre-mixed) diluted in saline (E). Again, the same
procedure is performed for 125I-labeled fatty acid tracer. Prepare duplicates of the following: 5–
10ml of the prepared 125I-labeled fatty acid tracer (pre-mixed) (A), 5–10ml of a 2 volume of the
prepared 125I-labeled fatty acid tracer (pre-mixed) diluted in saline (B), 5–10ml of a 4 volume of
the prepared 125I-labeled fatty acid tracer (pre-mixed) diluted in saline (C), 5–10ml of an 8
volume of the prepared 125I-labeled fatty acid tracer (pre-mixed) diluted in saline (D), and 5–10ml
of a 16 volume of the prepared 125I-labeled fatty acid tracer (pre-mixed) diluted in saline (E).
[52_TD$DIFF]3 Count the actual administered radioisotope activities. Note that 5ml of the injected isotopemixture
(triplicate) should be counted. Fill in the time of measurement and radioisotope activity on the ﬁrst
Excel sheet (see a Supplemental Excel ﬁle). Note: do not discard these tubes because they will be
needed for the second count.
4 After 2 or more days, perform a second 125I count (half-life = 60days) of both the sample and
standard tubes. Fill in the yellow-colored cells on the second Excel sheet (see also a Supplemental
Excel ﬁle). The activity of 18FDG during the second analysis is almost identical to the background
activity; hence, the count of 125I activity was not inﬂuenced by 18FDG activity.
Autoradiography
1. Prepare the 18F- or 125I-labeled graded standards. First, prepare the measured radioisotope. For
example, to evaluate 18FDG, 5ml of samples (A)–(E) are placed on ﬁlter paper. The spotted ﬁlter
paper is then sealed in a thin plastic wrap and placed on a sheet sized to ﬁt the imaging plate or
X-ray ﬁlm (arrow in Fig. 1A). In Fig. 1A, graded standards that contained only 18FDG were used
following preparation as described above ( [53_TD$DIFF]second method) in the section 2 in Measurement of
radioisotope activity using a scintillation counter. For 125I-labeled graded standards, previously
used graded standards (for example, an arrowhead in Fig.1A and 1B) are prepared and placed on the
sheet to account for the longer half-life.
2. Place serial 20-mm-thick transverse sections of methylcellulose-embedded mid-ventricle speci-
mens on a prepared slide with a glass coverslip (6 slices per heart). These prepared slides should be
attached to a paper sized to ﬁt the imaging plate along with the graded standards.
3. After preparing the paper sheet with attached slides and graded standards, place the sheet upside-
down on the imaging plate such that the covered glass or plastic membrane touches the imaging
plate or X-ray ﬁlm directly for 1h. Next, analyze the imaging plate using a computer-assisted
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imaging-processing system (BAS 1000, Fuji Photo Film Co., Ltd., Tokyo, Japan) to acquire photo-
stimulated luminescence or X-ray ﬁlm to acquire an image. If using the BAS system, a linear
correlation should be ﬁtted between the relative activities (Photo-Stimulated Luminescence; PSLs)
of the graded scales and actual radioisotopic activities (see detailed in explanation of the data sheet
and a Supplemental material). If using X-ray ﬁlm, densitometry should be performed, and the
results should be ﬁtted between the densities of the graded standards and actual radioisotopic
activities. The dose and energy of 18FDG is enough large that the activity of the 125I-labeled fatty acid
tracer might be negligible in the ﬁrst exposure (arrowhead in Fig. 1A).
4. After obtaining the 18FDG image (Fig. 1A), the imaging plate should be removed, and the next
exposure prepared.
5. After 2 or more days, perform the next exposure in the same way (Fig. 1B), using the above-
mentioned paper sheet. As the 18F will have completely decayed, all radioisotopic activity will be
derived solely from125I. The exposure time is longer than that used for 18F; for example, an exposure
of 3–4days is appropriate, due to the low injected dose and weak energy peak of 125I.
99mTc-sestamibi (MIBI) and 125I-labeled fatty acid tracer
If 99m [54_TD$DIFF] c-MIBI is used as an indicator of mitochondrial membrane potentials, which has a half-life of
6 h, an injected dose of 12.5 MBq (337.8mCi) per rat will not cause cross-talk with 125I-labeled fatty
acid tracer with an injected dose of 0.37 MBq (10mCi) [7]. The ﬁrst analysis is done to acquire 99mTc
activity. If using the Excel sheet, change 110, the half-life of 18FDG, to 240, the half-life of 99mTc, in the
calculation formula. Because of this longer half-life, 125I should be measured 7 or more days after the
ﬁrst experiment.[55_TD$DIFF]
(A) (Actual values at the start of the experiment) = (Measured values of samples) (0.5)(t/240),
where t is the elapsed time between the start of the experiment and themeasurement of the samples.
201Tl (thallium) and 125I–labeled fatty acid tracer
If 201 [56_TD$DIFF] l is used as a myocardial perfusion tracer, which has a half-life of 73h, an injected dose of
160–640mCi per rat will not cause cross-talk with 125I-labeled fatty acid tracer with an injected dose
of 16–64mCi per rat [8]. The ﬁrst analysis is done to acquire 201Tl activitywithin 11h. If using the Excel
sheet, change 110 (min), the half-life of 18FDG, to 4380 (min), the half-life of 201Tl, in the calculation
formula. [57_TD$DIFF]
(B) (Actual values at the start of the experiment) = (Measured values of samples) (0.5)(t/4380),
where t is the elapsed time between the start of the experiment and themeasurement of the samples.
Because of this longer half-life, 125I should be measured 30 or more days after the ﬁrst experiment.
The exposure time for autoradiography needs 3–4days in BAS systemand a longer period in X-rayﬁlm.
Explanation of the excel sheet
How to use this sheet attached as a Supplementary Excel ﬁle.
1. Open theﬁrst sheet. Fill in the date (cell B2), measured dose (cells B4 and B5 in units of Ci [curies]
and cells B7 and B8 in units of Bq [becquerels]), measured time (cells D4 and E4, D5 and E5 or
D7 and E7, D8 and E8), and number of injections prepared (numbers of animals plus 5, cell [58_TD$DIFF] 2).
Fill in the time at the start of the experiment (cell B12 and C12). Calculate the radioisotopic
activity at the start of the experiment (cells G4 and G5 or G7 and G8).
Calculation formulas are as follows:
For 125I activity: Because of the long decay time, the activity at the start of the experiment is
almost the same as that of the measurement (cells G4 and G7).
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For 18F activity:
(Actual values at the start of the experiment: cells G5 and G8) = (Measured values at the time of
measurement of preparation) (0.5)(t/110), (C)
where t is deﬁned as the elapsed time between the time of the start of the experiment and the
measurement (cell E13), and 110 is the half-decay time of 18F.
Calculate the radioisotopic counts of the injected isotope (cells N4 and N5 or N7 and N8)
according to the gamma camera counting efﬁciency (P4 and P5). The counting efﬁciency differs
for each camera; accordingly, each camera uses a different calculation formula. In general,
however, the radioisotopic counts of the injected isotope (cells N4 and N5 or N7 and N8)
should =Correcting coefﬁcient (the counting efﬁciency) x (actual values; L4 and L5 or L7 and L8)
(Eq. [59_TD$DIFF](D)).
2. Open the second sheet. Fill in the cells indicating the identiﬁcation number of each animal (cell
D6), animal group (cell C6), animal body weight (cell E6), date of the experiment (cell F6), the
time of the start of the experiment (cells W4 and X4), and blood sugar concentration (cell G6)
before injection.
3. After euthanization, record the weight of the whole heart into the appropriate cell (cell H6) in
the second Excel sheet. The mid-ventricle and apical one-third portions would be excised; the
latter is thenweighed, and this value is ﬁlled into the cell (cell I6) in the second sheet. Theweight
of the collected blood is also determined and entered into the second Excel sheet (cell J6); note
that the weight of the empty collection tube should be measured previously, and the weight of
blood should thus be corrected.
4. Measure the radioisotope activity of the heart and [60_TD$DIFF]blood ﬁll in the yellow-colored Excel cells (K6
to K11 andM6 toM [61_TD$DIFF] 1, Q6 toQ11 and S6 to S11, respectively) and the time ofmeasurement on the
second Excel sheet (cells O6 and P6). If the gamma counter expresses the actual values (such as
nCi orMBq) of the specimens, these values can beﬁlled in directly in cells L6 to L11 andN6 toN11
[62_TD$DIFF]or R6 to R11 and T6 to T11. Measure that of the blood sequentially.
5. Measure the activities of graded standards and record these values in the ﬁrst Excel sheet (cells
B23 to B27 and cells C23 to C27). Fill in the time of the measurement of graded standards
(B17 and C17). The actual values are calculated (cells F23 to F27 and F31 to F35) according to Eq. [63_TD$DIFF]
(D). The time after the experiment is calculated (cell E8). 18F at the start of the experiments is
calculated (cells H23 to H27 and cells J23 to J27). If the gamma counter expresses the actual
values (Bq) of the specimens, ﬁll in these values in cells F23 to F27. If the values have been
adapted to Ci, take care to replace Bq with Ci in the sheet.
6. Count the actual administered radioisotopic activities. A total of 5ml of the mixed isotopes
(triplicate) should be counted. Fill in the volume injected (cell B40 in the ﬁrst Excel sheet), the
volume of the measurement (cell B42), the time of measurement (cells B44 and C44) and
calculation (cell E45), and the radioisotopic activity (cells C49, C50, and C51) on the ﬁrst Excel
sheet. The average counts are calculated (C49) and then subsequently converted to the actual
values (cells F49 to F52), and the values at the start of the experiment are calculated (cell H52).
This value is converted to the injected value (cells M52 and N52). The 125I counts at the start of
the experiment are also calculated. Fill in these counts into cells B23 to B27 and calculate the
actual values (cells F31 to F35), or directly ﬁll in the actual values into cells F31 to F35.
7. Copy and paste data concerning the initial radioisotope activity (actual values) injected per
animal from the ﬁrst Excel sheet to the second Excel sheet (automatically ﬁlled into cells
Q37 and Q38 in the second Excel sheet).
8. On the second Excel sheet, calculate the activity per gram of tissue, the% dose/g, and SUV
(standard uptake value).[64_TD$DIFF]
(Actual values at the start: cell K18) = (Measured values of a sample: cell N6) *(0.5)(t/110), (E)
where t is the elapsed time (cells W6 or L18) between the start of the experiment and the
time of the measurement of the sample.
(Activity per gram) = (Actual values at the start of the experiment)/(tissue or blood weight [g])
294 T. Kato /MethodsX 3 (2016) 289–296
(the% dose/g) = (Activity per tissue gram)/(injected radioisotope activity)
(SUV) = (the% dose/g) (body weight)
9. During the second count for 125I activity, the 125I activity values should be ﬁlled in where
appropriate. Count the actual radioisotope activities of 5ml of the injected (mixed) radioisotope
(triplicate) and ﬁll in the ﬁrst Excel sheet (cells B62 to B64). In addition, ﬁll in the time of
measurement (cell B57) and calculation of days form the ﬁrst experiment (cell B58). The 125I at
the start of the experiments are calculated (cell H65) according to the [65_TD$DIFF]Eq. (F), and copy and paste
these data to the second sheet (cell Q37). [66_TD$DIFF]
(Activity at the experiment) = (measured activity) (0.5)(t/60) (F)
where t is deﬁned as the days from the ﬁrst experiment. 60 (days) is the half decay time of
125I.
10. Measure the 125I activities of the heart and blood, and ﬁll in these values (cells AD6 to AD11 and
AF6 to AF11, or directly into cells AE6 to AE11 and AF6 to AF11 if a gamma camera yields actual
values) and the date of measurement (cell AF3) on the second Excel sheet. On the second Excel
sheet, calculate the activity per gram of tissue, [67_TD$DIFF][42_TD$DIFF]according to Eq. (F).
11. For both 18FDG and 125I-labeled fatty acid tracer autoradiography, acquire the PSL and calculate
PSL/mm2. For X-ray ﬁlm, acquire the image and calculate the image density instead of the PSL
values. Calculate the PSL of the heart minus background PSL. This calculation is performed by
ﬁtting values to a standard curve generated using graded standards and their known
radioisotope activity levels. An example of the third and the fourth Excel sheets is provided in
Fig. 1A and B.
Discussions
Recent technical advantages have enabled system-wide measurements of metabolites in various
organisms [9–11]. Two tracers, one radioactive and one stable, are used in these experiments. The
advantages and disadvantages of these tracers are brieﬂy summarized in Table 1. Dual-tracermethods
do not limit the use of radioactive tracers, and both tracers can be used in a dual-tracermethod. In this
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